Toshimasa Hishiki Selected Research

Glucagon-Like Peptide-1 Receptor Agonists

12/2023	The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.
3/2022	Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Toshimasa Hishiki Research Topics

Disease

6	Type 2 Diabetes Mellitus (MODY) 12/2023 - 01/2019
5	Chronic Renal Insufficiency 10/2023 - 01/2019
1	Diabetes Mellitus 01/2021
1	Masked Hypertension 01/2019
1	Hypertension (High Blood Pressure) 01/2019
1	White Coat Hypertension 01/2019

Drug/Important Bio-Agent (IBA)

5	Glucose (Dextrose)FDA LinkGeneric 12/2023 - 01/2019
5	SodiumIBA 12/2023 - 01/2019
4	SymportersIBA 12/2023 - 01/2019
4	Sodium-Glucose Transport ProteinsIBA 10/2023 - 01/2019
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 12/2023 - 03/2022
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2019

Therapy/Procedure

1	Therapeutics 01/2019